MD ANDERSON INTERNATIONAL MEETING IN GYNECOLOGIC ONCOLOGY:
EMERGING THERAPIES IN GYNECOLOGICAL CANCER

LOCATE COMMITTEE:
• Sonsoles Alonso
• Marisa Argente
• Raquel Bratos
• Natalia Carballo
• Teresa Carrascosa
• Luis Chiva
• Virginia Cornejo
• Ana Corroto
• Irene Fernández
• Juan Fernando García
• Javier García Pardo
• Antonio González-Márquez
• Luis Granados
• Fernando Lapuente
• Mª José López de Paredes
• Reinal Márquez
• Alf Mardel
• Gema Moreno
• Mª Jesús Pablés
• Virginia Pelayo
• Alejandro Rojo
• Gemma Troncoso

LIST OF SPEAKERS AND MODERATORS:
• Nadeem Abu-Rustum
  MSKCC, New York, USA.
• José María del Campo
  Hospital Universitari Vall d’Hebron, Barcelona, Spain.
• Natalio Garayio
  MD Anderson Cancer Center Madrid, Spain.
• Dennis Chi
  MSKCC, New York, USA.
• Luis Chiva
  General Teaching Hospital of Prague, Charles University Prague, Prague, The Czech Republic.
• Robert Coleman
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Christine D’Avolio
  Imperial College London, United Kingdom.
• David Domínguez
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Antonio Gil-Moreno
  MD Anderson Cancer Center, Madrid, Spain.
• David Cibula
  General Teaching Hospital of Prague, Charles University Prague, Prague, The Czech Republic.
• Robert Coleman
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Karen Lu
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Anja Schmeler
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Joaquim de Paredes
  Hospital Universitari Vall d’Hebron, Barcelona, Spain.
• Jordi Ponce
  Hospital Universitari Bellvitge, Barcelona, Spain.
• Andrés Poveda
  Hospital Universitari Vall d’Hebron, Barcelona, Spain.
• Eric Pujade-Lauraine
  Centre Hospitalier Universitaire de Lille, Lille, France.
• Pedro Ramírez
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Francesca Rampaglia
  Istituto Nazionale dei Tumori, Milan, Italy.
• Alejandro Robleda
  Autonoma University Athens, Athens, Greece.
• Katharina Schmeler
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Katharina Schmeler
  Charité University Hospital, Berlin, Germany.
• Andi Sood
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Andi Sood
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Nadeem Abu-Rustum
  MSKCC, New York, USA.
• José María del Campo
  Hospital Universitari Vall d’Hebron, Barcelona, Spain.
• Natalio Garayio
  MD Anderson Cancer Center Madrid, Spain.
• Dennis Chi
  MSKCC, New York, USA.
• Luis Chiva
  General Teaching Hospital of Prague, Charles University Prague, Prague, The Czech Republic.
• Robert Coleman
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Christine D’avolio
  Imperial College London, United Kingdom.
• David Domínguez
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Antonio Gil-Moreno
  MD Anderson Cancer Center, Madrid, Spain.
• David Cibula
  General Teaching Hospital of Prague, Charles University Prague, Prague, The Czech Republic.
• Robert Coleman
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Karen Lu
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Anja Schmeler
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Joaquim de Paredes
  Hospital Universitari Vall d’Hebron, Barcelona, Spain.
• Jordi Ponce
  Hospital Universitari Bellvitge, Barcelona, Spain.
• Andrés Poveda
  Hospital Universitari Vall d’Hebron, Barcelona, Spain.
• Eric Pujade-Lauraine
  Centre Hospitalier Universitaire de Lille, Lille, France.
• Pedro Ramírez
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Francesca Rampaglia
  Istituto Nazionale dei Tumori, Milan, Italy.
• Alejandro Robleda
  Autonoma University Athens, Athens, Greece.
• Katharina Schmeler
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Katharina Schmeler
  Charité University Hospital, Berlin, Germany.
• Andi Sood
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Andi Sood
  The University of Texas MD Anderson Cancer Center, Houston, USA.

MD ANDERSON INTERNATIONAL MEETING IN GYNECOLOGIC ONCOLOGY:
EMERGING THERAPIES IN GYNECOLOGICAL CANCER

DIRECTORS:
• Dr. Luis Chiva
  Head of Department of Gynecologic Oncology
  MD Anderson Cancer Center, Madrid, Spain.
• Dr. Antonio González-Martin
  Head of Department of Medical Oncology
  MD Anderson Cancer Center, Madrid, Spain.
• Dr. Pedro Ramirez
  Director of Minimally Invasive Surgical Research & Education
  Department of Gynecologic Oncology
  The University of Texas MD Anderson Cancer Center, Houston, USA.

LIST OF SPEAKERS AND MODERATORS:
• Nadeem Abu-Rustum
  MSKCC, New York, USA.
• José María del Campo
  Hospital Universitari Vall d’Hebron, Barcelona, Spain.
• Natalio Garayio
  MD Anderson Cancer Center Madrid, Spain.
• Dennis Chi
  MSKCC, New York, USA.
• Luis Chiva
  General Teaching Hospital of Prague, Charles University Prague, Prague, The Czech Republic.
• Robert Coleman
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Christine D’avolio
  Imperial College London, United Kingdom.
• David Domínguez
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Antonio Gil-Moreno
  MD Anderson Cancer Center, Madrid, Spain.
• David Cibula
  General Teaching Hospital of Prague, Charles University Prague, Prague, The Czech Republic.
• Robert Coleman
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Karen Lu
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Anja Schmeler
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Joaquim de Paredes
  Hospital Universitari Vall d’Hebron, Barcelona, Spain.
• Jordi Ponce
  Hospital Universitari Bellvitge, Barcelona, Spain.
• Andrés Poveda
  Hospital Universitari Vall d’Hebron, Barcelona, Spain.
• Eric Pujade-Lauraine
  Centre Hospitalier Universitaire de Lille, Lille, France.
• Pedro Ramírez
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Francesca Rampaglia
  Istituto Nazionale dei Tumori, Milan, Italy.
• Alejandro Robleda
  Autonoma University Athens, Athens, Greece.
• Katharina Schmeler
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Katharina Schmeler
  Charité University Hospital, Berlin, Germany.
• Andi Sood
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Andi Sood
  The University of Texas MD Anderson Cancer Center, Houston, USA.

MD ANDERSON INTERNATIONAL MEETING IN GYNECOLOGIC ONCOLOGY:
EMERGING THERAPIES IN GYNECOLOGICAL CANCER

DIRECTORS:
• Dr. Luis Chiva
  Head of Department of Gynecologic Oncology
  MD Anderson Cancer Center, Madrid, Spain.
• Dr. Antonio González-Martin
  Head of Department of Medical Oncology
  MD Anderson Cancer Center, Madrid, Spain.
• Dr. Pedro Ramirez
  Director of Minimally Invasive Surgical Research & Education
  Department of Gynecologic Oncology
  The University of Texas MD Anderson Cancer Center, Houston, USA.

LIST OF SPEAKERS AND MODERATORS:
• Nadeem Abu-Rustum
  MSKCC, New York, USA.
• José María del Campo
  Hospital Universitari Vall d’Hebron, Barcelona, Spain.
• Natalio Garayio
  MD Anderson Cancer Center Madrid, Spain.
• Dennis Chi
  MSKCC, New York, USA.
• Luis Chiva
  General Teaching Hospital of Prague, Charles University Prague, Prague, The Czech Republic.
• Robert Coleman
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Christine D’avolio
  Imperial College London, United Kingdom.
• David Domínguez
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Antonio Gil-Moreno
  MD Anderson Cancer Center, Madrid, Spain.
• David Cibula
  General Teaching Hospital of Prague, Charles University Prague, Prague, The Czech Republic.
• Robert Coleman
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Karen Lu
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Anja Schmeler
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Joaquim de Paredes
  Hospital Universitari Vall d’Hebron, Barcelona, Spain.
• Jordi Ponce
  Hospital Universitari Bellvitge, Barcelona, Spain.
• Andrés Poveda
  Hospital Universitari Vall d’Hebron, Barcelona, Spain.
• Eric Pujade-Lauraine
  Centre Hospitalier Universitaire de Lille, Lille, France.
• Pedro Ramírez
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Francesca Rampaglia
  Istituto Nazionale dei Tumori, Milan, Italy.
• Alejandro Robleda
  Autonoma University Athens, Athens, Greece.
• Katharina Schmeler
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Katharina Schmeler
  Charité University Hospital, Berlin, Germany.
• Andi Sood
  The University of Texas MD Anderson Cancer Center, Houston, USA.
• Andi Sood
  The University of Texas MD Anderson Cancer Center, Houston, USA.
19–21 February 2014
MADRID
Auditorio Mutua Madrileña.

Directors:
Dr. Luis Chiva.
Head of Department of Gynecologic Oncology.
MD Anderson Cancer Center Madrid, Spain.

Dr. Antonio González-Martín.
Head of Department of Medical Oncology.
MD Anderson Cancer Center Madrid, Spain.

Dr. Pedro Ramírez.
Director of Minimally Invasive Surgical Research & Education.
Department of Gynecologic Oncology.
The University of Texas MD Anderson Cancer Center, Houston. USA.

LIST OF SPEAKERS AND MODERATORS:

• Nadeem Abu-Rustum
  MSKCC. New York, USA.

• José María del Campo
  Hospital Universitari Vall d’Hebron. Barcelona, Spain.

• Natalia Carballo
  MD Anderson Cancer Center Madrid, Spain.

• Dennis Chi
  MSKCC. New York, USA.

• Luis Chiva
  MD Anderson Cancer Center Madrid, Spain.

• David Cibula

• Robert Coleman
  The University of Texas MD Anderson Cancer Center. Houston, USA.

• Christine Potapová
  Imperial College London. United Kingdom.

• David Gershenson
  The University of Texas MD Anderson Cancer Center. Houston, USA.

• Ana Gil-Moreno
  MD Anderson Cancer Center Madrid, Spain.

• David Cibula

• Robert Coleman
  The University of Texas MD Anderson Cancer Center. Houston, USA.

• Christina Fotopoulou
  The Royal Marsden Hospital. Sutton, United Kingdom.

• Michael Gershenson
  The University of Texas MD Anderson Cancer Center. Houston, USA.

• Anna Oaknin
  Hospital Vall d’Hebrón. Barcelona, Spain.

• Jordi Ponce
  Hospital Universitari Bellvitge. Barcelona, Spain.

• Andrés Poveda

• Pedro Ramírez
  The University of Texas MD Anderson Cancer Center. Houston, USA.

• Francesco Raspagliesi
  Istituto Nazionale dei Tumori. Milan, Italy.

• Anil Sood
  The University of Texas MD Anderson Cancer Center. Houston, USA.

• Jalid Sehouli
  Charité University Hospital. Berlin, Germany.

• Kathleen Schmeler
  The University of Texas MD Anderson Cancer Center. Houston, USA.

• Anil Sood
  The University of Texas MD Anderson Cancer Center. Houston, USA.
WELCOME.

Role of HIPEC therapy: A new frontier or therapy with no future?

Dr. Stan Kaye. The Royal Marsden Hospital. Sutton, United Kingdom.

Dr. Pedro Ramirez. The University of Texas MD Anderson Cancer Center. Houston, USA.

DISCUSSION

Laparoscopic assessment prior to debulking: Should this be the new standard of care in ovarian cancer?


Memorial Experience.

Role of sentinel node in early-stage disease & surgical options in locally-advanced cervical cancer.

Dr. Anil Sood. The University of Texas MD Anderson Cancer Center. Houston, USA.

Dr. Michael Frumovitz. Memorial Sloan-Kettering Cancer Center. New York, USA.

Ovarian cancer:

• 14:00-14:15
  • Radical upper abdominal lymphadenectomy.
  • Dr. Fernando Lapuente. MD Anderson Cancer Center Madrid. Spain.

• 14:15-14:30
  • Sentinel lymphadenectomy in gynecological oncology.
  • Dr. Luis Chiva. MD Anderson Cancer Center Madrid. Spain.

Reconstructive surgery:

• 14:45-14:50
  • Single-port hysterectomy.
  • Dr. Luis Chiva. MD Anderson Cancer Center Madrid. Spain.

• 14:50-14:55
  • Coffee

Thursday, February 20, 2014

UPFRONT THERAPY IN OVARIAN CANCER

UPTIME 2014:

Dr. Pedro Ramírez. The University of Texas MD Anderson Cancer Center. Houston, USA.

10.00-10.15

Laparoscopic assessment prior to debulking: Should this be the new standard of care in advanced ovarian cancer?

Dr. Robert Coleman. The University of Texas MD Anderson Cancer Center. Houston, USA.

10.30-10.45

Role of HIPEC therapy: A new frontier or therapy with no future?

Dr. David Gershenson. The University of Texas MD Anderson Cancer Center. Houston, USA.

10.45-10.50

RNAi strategies in future therapeutics of ovarian cancer.

Dr. Anil Sood. The University of Texas MD Anderson Cancer Center. Houston, USA.

10.50-10.55

Coffee

10.55-11.10

New therapeutic options for specific ovarian subtypes: Low grade, clear cell andendometrioid.

Dr. David Fornace. The University of Texas MD Anderson Cancer Center. Houston, USA.

11.10-11.20

DISCUSSION

11.20-11.30

INTEGRATION OF ANTI-ANGIOGENIC THERAPY INTO FRONT-LINE OVARIAN CANCER TREATMENT

Dr. Eric Hague. City of Hope University Hospital. Toronto, France.

11.30-11.40

The ovarian cancer “moonshot” - A translational approach.

Dr. Paolo Colombo. The University of Texas MD Anderson Cancer Center. Houston, USA.

11.40-11.50

DISCUSSION

RECURRENT OVARIAN CANCER UPDATES ON MEDICAL AND SURGICAL OPTIONS

Dr. Robert Coleman. The University of Texas MD Anderson Cancer Center. Houston, USA.

Dr. Anil Sood. The University of Texas MD Anderson Cancer Center. Houston, USA.

12.00-12.10

Standard treatment and progression-guiding options in the medical management of recurrent ovarian cancer.

Dr. treadmill. MD Anderson University Hospital. MD Anderson Cancer Center. Houston, USA.

12.10-12.20

Use of anti-VEGF and other anti-angiogenic agents in recurrent ovarian cancer.

Dr. Alice Flaherty. Harvard Medical School. Boston, USA.

12.20-12.30

Indications for surgical resection of recurrent disease. Has criteria changed?

Dr. Yoshihisa Koyama. Imperial College London. United Kingdom.

12.30-12.40

Lunch

12.40-13.00

DISCUSSION

UPDATES AND INNOVATIONS IN THE MANAGEMENT OF CERVICAL CANCER

Dr. Andrea Mariani. Mayo Clinic. Minnesota, USA.

Dr. Anuja Pujade-Lauraine. MD Anderson Cancer Center. Houston, USA.

13.00-13.10

Role of sentinel lymph node in early-stage disease & surgical options in locally advanced cervical cancer.

Dr. Kathleen Schmeler. The University of Texas MD Anderson Cancer Center. Houston, USA.

13.10-13.20

Evolution of cervical cancer surgery. Tailoring radically to risk factors.

Dr. Dennis Chi. Memorial Sloan-Kettering Cancer Center. New York, USA.

13.20-13.30

Current indicators and latent technologies in radiation oncology.

Dr. Robert Coleman. The University of Texas MD Anderson Cancer Center. Houston, USA.

13.30-13.40

Standard and novel therapeutics in advanced or recurrent cervical cancer.

Dr. Jennifer Wanebo. MD Anderson Cancer Center. Houston, USA.

13.40-13.50

Lunch

13.50-14.10

DISCUSSION

DISCUSSING CONTROVERSIAL TOPICS IN ENDOMETRIAL CANCER

Dr. Michael Frumovitz. Memorial Sloan-Kettering Cancer Center. New York, USA.

14.10-14.20

Endometrial lymphangiography and role of lymphatic mapping in endometrial cancer.

Dr. David Gershenson. The University of Texas MD Anderson Cancer Center. Houston, USA.

14.20-14.30

Memorial Experience.

Dr. Rebecca Rosenschein. MD Anderson. New York, USA.

14.30-14.40

DISCUSSION

14.40-14.50

Coffee

14.50-15.10

PREVENTION AND THERAPY OF GYNECOLOGICAL CANCER IN DEVELOPING COUNTRIES: LIMITATIONS TO DISEASE CONTROL AND MANAGEMENT CHANGING the world of cervical cancer: Technology for everyone.

The Central American experience.

Dr. Kathleen Schmeler. The University of Texas MD Anderson Cancer Center. Houston, USA.

The Indian experience.

Dr. Sukalya spicy. National Cancer Center. Mumbai, India.

International experience.

Dr. Sarah Warrick. University of North Carolina. Chapel Hill, USA.

Dr. Michela Torlai. Istituto Nazionale dei Tumori. Milan, Italy.

Dr. Nikos Koss. The University of Texas MD Anderson Cancer Center. Houston, USA.

Dr. Latif Shehata. University of South Carolina. Columbia, USA.

15.10-15.20

Coffee

15.20-15.30

MOVEMBER MD ANDERSON FOUNDATION SPAIN AWARDS 2014

A chance to do a great good work.

Gynecological oncology award:

• The gynecologic oncology perspective.
  • Dr. Alejandro Gil-Moreno. Hospital Vall d’Hebron. Barcelona, Spain.
  • Dr. Andrés Poveda. Instituto Valenciano de Oncología. Valencia, Spain.

• The gynecologic oncology award.
  • Dr. Jose Miguel Calafell. Hospital Clínic de Barcelona. Spain.
  • Dr. Anna Balaguer. Hospital Universitari i Politecnico La Fe. Valencia, Spain.

15.30-15.40

TUMOR BOARD

15.40-15.50

Discussion

15.50-16.00

Closing remarks

Dr. David Gershenson. The University of Texas MD Anderson Cancer Center. Houston, USA.

Dr. Anil Sood. The University of Texas MD Anderson Cancer Center. Houston, USA.

Dr. Jonathan Ledermann. University College London. United Kingdom.

16.00-16.15

Coffee

16.15-17.00

DISCUSSION

17.00-17.10

DISCUSSION

17.10-17.15

Closing remarks

Dr. David Gershenson. The University of Texas MD Anderson Cancer Center. Houston, USA.

Dr. Anil Sood. The University of Texas MD Anderson Cancer Center. Houston, USA.

Dr. Jonathan Ledermann. University College London. United Kingdom.

17.15-17.30

Coffee

17.30-18.00

MD Anderson Experience.

Dr. Pedro Ramírez. The University of Texas MD Anderson Cancer Center. Houston, USA.

18.00-18.15

European Experience.

Dr. Francisco Ramírez. Instituto Nacional de Cataratas. Madrid, Italy.

18.15-18.30

Adjuvant therapy for intermediate and high risk endometrial cancer.

Dr. Andrea Mariani. Mayo Clinic. Minnesota, USA.

18.30-18.45

Coffee

18.45-19.00

DISCUSSION

19.00-19.15

Coffee

19.15-20.00

MONDAY EVENING SOCIAL
IV MD ANDERSON INTERNATIONAL MEETING IN GYNECOLOGIC ONCOLOGY

Wednesday-February 19, 2014

12.30-13.30
SURGICAL SYMPOSIUM: INNOVATIVE & COMPLEX PROCEDURES IN GYNECOLOGIC ONCOLOGY

13.15-13.30
Introduction
Dr. Gustavo Rodriguez-Acosta. The University of Texas MD Anderson Cancer Center. Houston, USA.

13.30-13.45
Standard treatment and promising non-antiangiogenesis options in the medical DISCUSSION

13.45-14.15
Low grade, clear cell and WELCOME.
Novel therapeutic options for specific ovarian subtypes: Dr. Jonathan Lerman. University of California, Los Angeles, USA.

14.15-15.15

15.15-15.30
Coffee
Dr. Pedro Ramirez. The University of Texas MD Anderson Cancer Center. Houston, USA.

15.30-16.30
Future clinical trial designs and biomarkers for anti-angiogenic therapy. Dr. Stan Kaye. The Royal Marsden Hospital. Sutton, United Kingdom.

16.30-16.45
Lunch

16.45-17.45
Reconstructive surgery: What is the future ahead? Dr. Michael Frumovitz. The University of Texas MD Anderson Cancer Center. Houston, USA.

Thursday, February 20, 2014

13.00-15.30
Lunch

15.30-17.30
UPFRONT THERAPY IN OVARIAN CANCER

15.30-15.50
Surgical node mapping: understanding the anatomy behind it. Dr. Robert Coleman. The University of Texas MD Anderson Cancer Center. Houston, USA.

15.50-16.10
Laparoscopic assessment prior to debulking: Should this be the new standard of care in Dr. Debrah Dimick. Mayo Clinic. Phoenix, USA.

16.10-16.30

16.30-16.45
Coffee

16.45-17.05
Dr. Andrew Fisher. The University of Texas MD Anderson Cancer Center. Houston, USA.

17.05-17.25
Role of preoperative imaging in the management of advanced ovarian cancer. Dr. Antonio González-Martín. MD Anderson Cancer Center Madrid, Spain.

17.25-17.45
Novel approaches to peritoneal surface dissemination in ovarian cancer. Dr. José Manuel Font. Hospital Universitari Vall d’Hebron. Barcelona, Spain.

17.45-18.05
Coffee

18.05-18.25
Dr. Christian Tutt. Harvard Medical School. Boston, USA.

18.25-18.45
Dr. Nadeem Abu-Rustum. MSKCC. New York, USA.

18.45-19.05
Lunch

19.05-21.05
INTEGRATION OF ANTI-ANGIOGENIC THERAPY INTO FRONT-LINE OVARIAN CANCER TREATMENT

19.05-20.05
Mr. Adrian Young. University of Oxford. Oxford, United Kingdom.

20.05-21.05
Dr. Nadeem Abu-Rustum. MSKCC. New York, USA.

21.05-21.25
Dr. Dennis Chi. MSKCC. New York, USA.

21.25-21.45
Lunch

21.45-22.45
Closing remarks

Thursday, February 21, 2014

10.00-10.25
DISCUSSION

10.25-10.45
Dr. Michael Frumovitz. The University of Texas MD Anderson Cancer Center. Houston, USA.

10.45-11.05
Moderators:

11.05-11.25
Closing remarks

11.25-11.45
Coffee

11.45-12.05
Prevention and therapy of gynecologic cancer in developing countries: when limitations lead to innovation Changing the world of cervical cancer Technology for everyone.

The Central American experience Dr. Judith Salazar. The University of San Francisco. San Francisco, USA.

The Indian experience. Dr. Supriya Gupta. Taj Fork Club Memorial. Mumbai, India.

International perspective. Dr. José María del Campo. Hospital Universitario Vall d´Hebron. Barcelona, Spain.

12.05-12.25
Dr. Ricardo dos Reis. Hospital de Câncer de Barretos. Brazil.

12.25-12.45
Dr. Marcelo Vivanco. Hospital de Câncer de Barretos. Brazil.

12.45-13.05
Lunch

13.05-14.05
DISCUSSING CONTROVERSIAL TOPICS IN ENDOMETRIAL CANCER

13.05-13.25
Moderators:

13.25-13.45
Dr. Karen Kastan. Emory University. Atlanta, USA.

13.45-13.55

13.55-14.15
Dr. Rudolph Berry. The University of Texas MD Anderson Cancer Center. Houston, USA.

14.15-14.35
Dr. Andrea Mariani. Mayo Clinic. Minnesota, USA.

14.35-14.55
Dr. Karen Kastan. Emory University. Atlanta, USA.

14.55-15.15
Lunch

15.15-16.15
DISCUSSING CONTROVERSIAL TOPICS IN ENDOMETRIAL CANCER

15.15-15.35
Moderators:

15.35-15.55
Dr. Karen Kastan. Emory University. Atlanta, USA.

15.55-16.15

16.15-16.35
Dr. Andrea Mariani. Mayo Clinic. Minnesota, USA.

16.35-16.55
Dr. Karen Kastan. Emory University. Atlanta, USA.

16.55-17.15
Lunch

17.15-18.15
DISCUSSING CONTROVERSIAL TOPICS IN ENDOMETRIAL CANCER

17.15-17.35
Moderators:

17.35-17.55
Dr. Karen Kastan. Emory University. Atlanta, USA.

17.55-18.15

18.15-18.35
Dr. Andrea Mariani. Mayo Clinic. Minnesota, USA.

18.35-18.55
Dr. Karen Kastan. Emory University. Atlanta, USA.

18.55-19.15
Lunch
Wednesday-Friday, February 19, 2014

10.00-10.25

10.35-11.00

11.20-11.40

11.50-12.05

12.15-12.20

12.30-13.30

13.45-14.00

14.00-14.15

14.15-14.30

14.30-14.45

15.00-15.15

15.20-15.35

15.40-15.50

16.10-16.20

16.20-16.40

16.40-17.00

17.10-17.20

17.20-17.30

17.30-17.45

17.45-18.00

18.00-18.15

18.45-19.15

Thursday-February 20, 2014

10.00-10.25

10.35-11.00

11.20-11.40

11.50-12.05

12.15-12.20

12.30-13.30

13.45-14.00

14.00-14.15

14.15-14.30

14.30-14.45

15.00-15.15

15.20-15.35

15.40-15.50

16.10-16.20

16.20-16.40

16.40-17.00

17.10-17.20

17.20-17.30

17.30-17.45

17.45-18.00

18.00-18.15

18.45-19.15

19.30-20.00

Friday-February 21, 2014

10.00-10.25

10.35-11.00

11.20-11.40

11.50-12.05

12.15-12.20

12.30-13.30

13.45-14.00

14.00-14.15

14.15-14.30

14.30-14.45

15.00-15.15

15.20-15.35

15.40-15.50

16.10-16.20

16.20-16.40

16.40-17.00

17.10-17.20

17.20-17.30

17.30-17.45

17.45-18.00

18.00-18.15

18.45-19.15

19.30-20.00

1. An overview of new and emerging antiangiogenic strategies in ovarian cancer.

2. Standard treatment and promising non-antiangiogenesis options in the medical management of recurrent disease.

3. Role of sentinel node in early-stage disease & surgical options in locally-advanced disease.

4. Oncological implications of extended pelvic resection.


6. Laparoscopic assessment prior to debulking: Should this be the new standard of care in recurrent ovarian cancer?

7. Systematic review and meta-analysis of the prognostic value of tumor angiogenesis in the medical management of recurrent disease in ovarian cancer.

8. Use of anti-VEGF and other anti-angiogenic agents for relapsed ovarian cancer.


10. Use of anti-angiogenic agents in the medical management of recurrent disease.

11. Update on role of PARP inhibition: The translational perspective.

12. Immunohistochemical analysis to assess tumor microenvironment in advanced ovarian cancer.

13. Review of new therapeutic options for germline ovarian subtypes: Low grade, clear cell and endometrioid.


15. Update on role of PARP inhibition: The translational perspective.

16. Analysis of circulating tumor cells and tumor angiogenesis in recurrent ovarian carcinoma.

17. New data on prognostic markers for survival in ovarian cancer.

18. Updos and updates in the management of cervical cancer.

19. Integrating new data on paraneoplastic manifestations in ovarian cancer.


32. Current indications and latest technologies in radiation oncology.


34. Current indications and latest technologies in radiation oncology.

35. Current indications and latest technologies in radiation oncology.


38. Current indications and latest technologies in radiation oncology.


41. Current indications and latest technologies in radiation oncology.

42. Current indications and latest technologies in radiation oncology.

43. Current indications and latest technologies in radiation oncology.

44. Current indications and latest technologies in radiation oncology.

45. Current indications and latest technologies in radiation oncology.

46. Current indications and latest technologies in radiation oncology.

47. Current indications and latest technologies in radiation oncology.


49. Current indications and latest technologies in radiation oncology.

DISCUSSION
Dr. Stan Kaye. The Royal Marsden Hospital. Sutton, United Kingdom.

PREVENTION AND THERAPY OF GYNECOLOGICAL CANCER IN DEVELOPING COUNTRIES: WHEN LIMITATIONS LEAD TO INNOVATION
Dr. Alejandro Arriagada. Hospital Universitario de Columbia. Bogota, Colombia.

UPFRONT THERAPY IN OVARIAN CANCER
Dr. Pedro Ramirez. The University of Texas MD Anderson Cancer Center. Houston, USA.

Laparoscopic assessment prior to debulking: should this be the new standard of care in advanced ovarian cancer? Dr. Antonio González-Martín. MD Anderson Cancer Center Madrid. Spain.


Coffee

UPFRONT THERAPY IN OVARIAN CANCER
Dr. Pedro Ramirez. The University of Texas MD Anderson Cancer Center. Houston, USA.

Laparoscopic assessment prior to debulking: should this be the new standard of care in advanced ovarian cancer? Dr. Antonio González-Martín. MD Anderson Cancer Center Madrid. Spain.


Coffee

INTRODUCTION
Dr. Joao Alves. The Royal Marsden Hospital. Sutton, United Kingdom.

MOLECULAR DISCOVERIES IN GYNECOLOGICAL MALIGNANCIES AND CANCER BIOLOGY
Dr. Denis Cibula. General Teaching Hospital in Prague. Prag. Czech Republic.

DISCUSSION
Dr. Robert Coleman. The University of Texas MD Anderson Cancer Center. Houston, USA.

ONCOLOGY: EMERGING THERAPIES IN GYNECOLOGICAL CANCER
Dr. David Cibula. General Teaching Hospital in Prague. Prag. Czech Republic.


Coffee

UPFRONT THERAPY IN OVARIAN CANCER
Dr. Pedro Ramirez. The University of Texas MD Anderson Cancer Center. Houston, USA.

Laparoscopic assessment prior to debulking: should this be the new standard of care in advanced ovarian cancer? Dr. Antonio González-Martín. MD Anderson Cancer Center Madrid. Spain.


Coffee

INTRODUCTION
Dr. Joao Alves. The Royal Marsden Hospital. Sutton, United Kingdom.

MOLECULAR DISCOVERIES IN GYNECOLOGICAL MALIGNANCIES AND CANCER BIOLOGY
Dr. Denis Cibula. General Teaching Hospital in Prague. Prag. Czech Republic.

DISCUSSION
Dr. Robert Coleman. The University of Texas MD Anderson Cancer Center. Houston, USA.

ONCOLOGY: EMERGING THERAPIES IN GYNECOLOGICAL CANCER
Dr. David Cibula. General Teaching Hospital in Prague. Prag. Czech Republic.


Coffee

UPFRONT THERAPY IN OVARIAN CANCER
Dr. Pedro Ramirez. The University of Texas MD Anderson Cancer Center. Houston, USA.

Laparoscopic assessment prior to debulking: should this be the new standard of care in advanced ovarian cancer? Dr. Antonio González-Martín. MD Anderson Cancer Center Madrid. Spain.


Coffee

INTRODUCTION
Dr. Joao Alves. The Royal Marsden Hospital. Sutton, United Kingdom.

MOLECULAR DISCOVERIES IN GYNECOLOGICAL MALIGNANCIES AND CANCER BIOLOGY
Dr. Denis Cibula. General Teaching Hospital in Prague. Prag. Czech Republic.

DISCUSSION
Dr. Robert Coleman. The University of Texas MD Anderson Cancer Center. Houston, USA.

ONCOLOGY: EMERGING THERAPIES IN GYNECOLOGICAL CANCER
Dr. David Cibula. General Teaching Hospital in Prague. Prag. Czech Republic.


Coffee

UPFRONT THERAPY IN OVARIAN CANCER
Dr. Pedro Ramirez. The University of Texas MD Anderson Cancer Center. Houston, USA.

Laparoscopic assessment prior to debulking: should this be the new standard of care in advanced ovarian cancer? Dr. Antonio González-Martín. MD Anderson Cancer Center Madrid. Spain.


Coffee

INTRODUCTION
Dr. Joao Alves. The Royal Marsden Hospital. Sutton, United Kingdom.

MOLECULAR DISCOVERIES IN GYNECOLOGICAL MALIGNANCIES AND CANCER BIOLOGY
Dr. Denis Cibula. General Teaching Hospital in Prague. Prag. Czech Republic.

DISCUSSION
Dr. Robert Coleman. The University of Texas MD Anderson Cancer Center. Houston, USA.

ONCOLOGY: EMERGING THERAPIES IN GYNECOLOGICAL CANCER
Dr. David Cibula. General Teaching Hospital in Prague. Prag. Czech Republic.


Coffee
MD ANDERSON INTERNATIONAL MEETING IN GYNECOLOGIC ONCOLOGY:
EMERGING THERAPIES IN GYNECOLOGICAL CANCER

DIRECTORS:
Dr. Luis Chiva. Head of Department of Gynecologic Oncology, MD Anderson Cancer Center Madrid, Spain.
Dr. Antonio González-Martín. Head of Department of Medical Oncology, MD Anderson Cancer Center Madrid, Spain.

DIRECTORS:
Dr. Pedro Ramírez. Director of Minimally Invasive Surgical Research & Education, Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.

LIST OF SPEAKERS AND MODERATORS:
Nadeem Abu-Rustum. MSKCC. New York, USA.
José María del Campo. Hospital Universitario Vall d’Hebron. Barcelona, Spain.
Natalia Carballo. MD Anderson Cancer Center Madrid, Spain.
Dennis Chi. MSKCC. New York, USA.
Luis Chiva. MD Anderson Cancer Center Madrid, Spain.
David Cibula. General Teaching Hospital Prague. Prague, Czech Republic.
Robert Coleman. The University of Texas MD Anderson Cancer Center. Houston, USA.
Christine Potapova. Imperial College London. United Kingdom.
Michael Pumplin. The University of Texas MD Anderson Cancer Center. Houston, USA.
David Gershenson. The University of Texas MD Anderson Cancer Center. Houston, USA.
Antonio González-Martín. MD Anderson Cancer Center Madrid, Spain.
Sudeep Gupta. Tata Memorial Centre Mumbai, India.
Anuja Jhingran. The University of Texas MD Anderson Cancer Center. Houston, USA.
Stan Kaya. The Royal Marsden Hospital. Sutton, United Kingdom.
Fernando Lapuente. MD Anderson Cancer Center Madrid, Spain.
Jonathan Ledermann. UCL Cancer Institute, University College London, United Kingdom.
Karen Lu. The University of Texas MD Anderson Cancer Center. Houston, USA.
Antonio Mariani. Hospital Universitario Vall d’Hebron. Barcelona, Spain.
Manolos Miscas. Rigshospitalet. Copenhagen, Denmark.
Ana Oaknin. Hospital Universitario Vall d’Hebron. Barcelona, Spain.
Jordi Ponce. Hospital Universitari Bellvitge. Barcelona, Spain.
Pedro Ramírez. The University of Texas MD Anderson Cancer Center. Houston, USA.
Francesco Raspagliesi. Istituto Nazionale dei Tumori. Milan, Italy.
Alexandros Rodolakis. Alexandros Hospital. Athens, Greece.
Kathleen Schmeler. The University of Texas MD Anderson Cancer Center. Houston, USA.
Jalid Sehouli. Charité University Hospital. Berlin, Germany.
Anil Sood. The University of Texas MD Anderson Cancer Center. Houston, USA.

LOCAL COMMITTEE:

www.mdanderson.es/international-meeting-in-gynecologic-oncology
MD ANDERSON INTERNATIONAL MEETING IN GYNECOLOGIC ONCOLOGY:
EMERGING THERAPIES IN GYNECOLOGICAL CANCER

19 - 21 February 2014
MADRID

LIST OF SPEAKERS AND MODERATORS:

- Nadeem Abur-Rustum
  MSKCC. New York, USA.
- José María del Campo
  Hospital Universitario Vall d’Hebron. Barcelona, Spain.
- Natalia Carballo
  MD Anderson Cancer Center Madrid, Spain.
- Dennis Chi
  MSKCC. New York, USA.
- Luis Chiva
  MD Anderson Cancer Center Madrid, Spain.
- David Cibula
  General Teaching Hospital in Prague. Czech Republic.
- Robert Coleman
  The University of Texas MD Anderson Cancer Center. Houston, USA.
- Christine D’Cruz
  Imperial College London, United Kingdom.
- David Eifel
  The University of Texas MD Anderson Cancer Center. Houston, USA.
- Antonio Gil-Moreno
  MD Anderson Cancer Center Madrid, Spain.
- David Gershenson
  The University of Texas MD Anderson Cancer Center. Houston, USA.
- Antonio González-Martín
  Hospital Vall d’Hebron. Barcelona, Spain.
- Sudeep Gupta
  Tata Memorial Centre Mumbai, India.
- Anuja Jhingran
  The University of Texas MD Anderson Cancer Center. Houston, USA.
- Stan Kaye
  The Royal Marsden Hospital. Sutton, United Kingdom.
- David Cibula
  General Teaching Hospital in Prague. Czech Republic.
- Robert Coleman
  The University of Texas MD Anderson Cancer Center. Houston, USA.
- Christina Fotopoulou
  Imperial College London, United Kingdom.
- Michael Fink
  MD Anderson Cancer Center Madrid, Spain.
- Robert Greenberg
  Mayo Clinic. Minnesota, USA.
- Joelle Lapide
  Centre Hospitalier Universitaire Armand-Frappier. Montreal, Canada.
- Pedro Ramirez
  The University of Texas MD Anderson Cancer Center. Houston, USA.
- Francesco Raspagliesi
  Istituto Nazionale dei Tumori. Milan, Italy.
- Alexandros Rodolakis
  Alexandra Hospital. Athens University. Athens, Greece.
- Kathleen Schmeler
  The University of Texas MD Anderson Cancer Center. Houston, USA.
- Jalid Sehouli
  Charité University Hospital. Berlin, Germany.
- Anil Sood
  The University of Texas MD Anderson Cancer Center. Houston, USA.
- Ana María Troncoso
  Hospital Universitario Vall d’Hebron. Barcelona, Spain.
- Jordi Vidal
  Hospital Universitario Bellvitge. Barcelona, Spain.
- Martín Viollet
- Joao Vivanco
  Hospital Universitario Ntra. Sra. de Valme. Seville, Spain.
- Natalia Carballo
  MD Anderson Cancer Center Madrid, Spain.
- Robert Coleman
  The University of Texas MD Anderson Cancer Center. Houston, USA.
- Virginia Corraliza
  Hospital Universitario Vall d’Hebron. Barcelona, Spain.
- Ana Cortijo
  Hospital Universitario Vall d’Hebron. Barcelona, Spain.
- Irene Fernández
  Hospital Universitario Bellvitge. Barcelona, Spain.
- Juan Fernando García
  Hospital Universitario Vall d’Hebron. Barcelona, Spain.
- Javier García-Padilla
  Hospital Universitario Vall d’Hebron. Barcelona, Spain.
- Antonio González-Martín
  Hospital Universitario Ntra. Sra. de Valme. Seville, Spain.
- Luis Granados
  Hospital Universitario Bellvitge. Barcelona, Spain.
- Fernando Lapuente
  MD Anderson Cancer Center Madrid, Spain.
- Mª José López de la Cuesta
  Hospital Universitario Bellvitge. Barcelona, Spain.
- Marisa Argente
  Hospital Universitario Bellvitge. Barcelona, Spain.
- Raquel Bratos
  Hospital Universitario Bellvitge. Barcelona, Spain.
- Natalia Carballo
  MD Anderson Cancer Center Madrid, Spain.
- Teresa Castellanos
  Hospital Universitario Bellvitge. Barcelona, Spain.